Skip to main content

ColoCare Data Warehouse

The ColoCare Study has a virtual, centralized data warehouse which coordinates data acquisition, integration, secure sharing, and access, while implementing high standards. The ColoCare Data Warehouse domains include demographic information, patient recruitment and follow-up, biometrics, diagnosis, treatments and outcomes, questionnaires, and biorepository. The ColoCare Data Warehouse will be the primary source for sharing ColoCare Study data, outlined below.

Types of Study Data Available

  • Questionnaire data are collected directly from participants in the ColoCare Study. These include data that may not be available routinely in medical records such as diet and supplement use; physical activity and derived data such as energy expenditure estimates; individual-level socioeconomic status variables such as educational attainment; quality of life and depression; social support; self-reported outcomes, e.g., recurrences; and other domains.
  • Clinical data include data from medical records.
  • Outcomes data include data on recurrence or progression, deaths and cause of death, and potentially other outcomes such as time to treatment or comorbid conditions.
  • Biospecimens include tumor and normal tissue, blood samples, urine samples, stool samples, and saliva samples (at some sites) at repeat time points. Biospecimens will be made available to researchers who are interested in requesting biospecimens as part of a research project request. The metadata on biospecimen availability will help external researchers plan potential projects and could be used for power calculations.

ColoCare Patient Characteristics

The patient characteristics of the ColoCare Study recruited at six US sites and one German site as of January 31, 2023 are provided below.

ColoCare Patient Characteristics as of January 31, 2023
Patient Characteristics* Total (N=3,715)
Age at diagnosis, n (%)
≤ 39 265 (7%)
40-49 610 (16%)
50 114 (3%)
51-59 879 (24%)
60-69 1001 (27%)
≥70 846 (23%)
Sex, n (%)
Male 2055 (55%)
Female 1660 (45%)
Race, n (%)
American Indian/Alaska Native 23 (1%)
Asian 111 (3%)
Native Hawaiian/ Pacific Islander 14 (0%)
Black or African American 282 (8%)
White 3188 (86%)
More than One Race 32 (1%)
Other 44 (1%)
Unknown 14 (0%)
Did not answer 0 (0%)
Pending / To be abstracted 7 (0%)
Ethnicity, n (%)
Not Hispanic 3512 (95%)
Hispanic or Latino 163 (4%)
Unknown 34 (1%)
Did not answer 0 (0%)
Pending / To be abstracted 6 (0%)
Tumor Location, n (%)
Colon 1902 (51%)
Rectum and Rectosigmoid 1733 (47%)
Pending / To be abstracted 80 (2%)
Tumor Stage at Diagnosis, n (%)†
I 563 (15%)
II 788 (21%)
III 1185 (32%)
IV 647 (17%)
0/In situ/polyps 132 (4%)
Pending / To be abstracted 400 (11%)
Primary Surgery, n (%)
Yes 3307 (89%)
No 226 (6%)
Pending / To be abstracted 182 (5%)
Resection Status, n (%)**
R0 (Margins clear) 2329 (63%)
R1/R2 (Tumor cells in margins) 164 (4%)
Rx 183 (5%)
Pending / To be abstracted 1039 (28%)
Neoadjuvant Treatment, n (%)
Colon 224 (6%)
Rectum and Rectosigmoid 992 (27%)
Pending / To be abstracted 2 (0%)
Adjuvant Treatment, n (%)
Colon 795 (21%)
Rectum and Rectosigmoid 660 (18%)
Pending / To be abstracted 1 (0%)
Body Mass Index (BMI), n (%)
Underweight (< 18.5) 71 (2%)
Normal Weight (18.5-24.9) 937 (25%)
Overweight (25.0-29.9) 1246 (34%)
Obese (>30.0) 1178 (32%)
Pending / To be abstracted 283 (8%)
Residency, n (%)***
Rural 379 (19%)
Urban 1447 (73%)
Pending / To be abstracted 67 (NA%)

*Recruited at six US sites (HCI, Moffitt, FredHutch, Cedars, WashU, and Tennessee) and one German site (Heidelberg).
†Clinical stage for patients receiving neoadjuvant therapy; Pathological stage for all others
**Due to off-site surgery, the sum of resection status may not equal the number of primary resections.
***Information on Urban/Rural area available for US sites only (n=1,988).